40 ERIE STREET, CAMBRIDGE, MA
Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema
Stockholders Elect Muna Bhanji, Brian Goff, and Jesse Goodman as Directors
Announces First Quarter 2026 Financial Results and Business Updates
Intellia Therapeutics Enters Underwriting Agreement for Public Offering
Reg. FD, Other Events
Amendments to By-laws Adopted by Intellia Therapeutics Board
Announces FDA Lift of Clinical Hold on MAGNITUDE Phase 3 Clinical Trial in ATTR-CM
Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates
Q1
FY 2024
Q3
Q2
FY 2023
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Confidential Treatment Order
Correspondence
Submission Upload